Novo Nordisk’s weight-loss drug Wegovy has launched in SA, where obesity affects nearly half of adults, but the company is facing competition from existing treatments and other market players. Business Day TV spoke to Novo Nordisk’s head of legal, ethics, compliance and quality, Jonas Lind Hansen, for more insight.
WATCH: Novo’s Wegovy enters SA’s weight-loss market
Business Day TV speaks to Jonas Lind Hansen, Novo Nordisk’s head of legal, ethics, compliance & quality, for more insights
Editor’s Choice
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.